Devchand Paul

2.4k citations

34 papers · 1.0k indexed · h-index 16

Impact in

Oncology top 5%
- Bone health and treatments
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
Orthopedics and Sports Medicine top 5%
- Bone health and osteoporosis research

Papers in ⓘ

Cancer Research 14
- Breast Cancer Treatment Studies 14
- Cancer Genomics and Diagnostics 3
Oncology 23
- Cancer Treatment and Pharmacology 13
- HER2/EGFR in Cancer Research 13
- Bone health and treatments 5
- Colorectal Cancer Treatments and Studies 3

Co-authors: Silvana Spadafora (4 shared papers)Georgiana K. Ellis (3 shared papers)Rowan T. Chlebowski (3 shared papers)Michelle Fan (3 shared papers)Henry G. Bone (2 shared papers)J. W. G. Smith (1 shared paper)Susie Jun (1 shared paper)Scot Sedlacek (14 shared papers)
Journals: Journal of Clinical Oncology (9 papers)Clinical Breast Cancer (5 papers)Cancer Research (3 papers)Breast Cancer Research and Treatment (3 papers)International Journal of Radiation Oncology*Biology*Physics (2 papers)
Partner nations: United States United Kingdom Peru

In The Last Decade

Devchand Paul

34 papers receiving 1.0k citations

Peers

Countries citing papers authored by Devchand Paul

Since Specialization

Citations

This map shows the geographic impact of Devchand Paul's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Devchand Paul with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Devchand Paul more than expected).

Fields of papers citing papers by Devchand Paul

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Devchand Paul. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Devchand Paul. The network helps show where Devchand Paul may publish in the future.

Co-authors

The 25 scholars most cited alongside Devchand Paul, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Devchand Paul Line = papers co-authored together Devchand Paul links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 34 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Randomized Trial of Denosumab in Patients Receiving Adjuvant Aromatase Inhibitors for Nonmetastatic Breast Cancer Journal of Clinical Oncology ·Georgiana K. Ellis, Henry G. Bone, Rowan T. Chlebowski, Devchand Paul, Silvana Spadafora, J. W. G. Smith, Michelle Fan, Susie Jun	2008	342
2	Sunitinib Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel for First-Line Treatment of Patients With Advanced Breast Cancer: A Phase III, Randomized, Open-Label Trial Clinical Breast Cancer ·Nicholas J. Robert, Mansoor N. Saleh, Devchand Paul, Daniele Generali, Laurent Gressot, Mehmet S Copur, Adam Brufsky, Susan Minton, Jeffrey K. Giguere, John W. Smith, Paul Richards, Diana Gernhardt, Xin Huang, Katherine Liau, Kenneth A. Kern, Jason J. Davis	2011	94
3	Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study The Lancet Oncology ·Stephen E. Jones, Rufus Collea, Devchand Paul, Scot Sedlacek, Anne Favret, Ira Gore, Deborah Lindquist, Frankie A. Holmes, Mary Ann Allison, Barry Don Brooks, Raul M Portillo, Svetislava J. Vukelja, Michael S. Steinberg, Christopher Stokoe, M Crockett, Yunfei Wang, Lina Asmar, Nicholas J. Robert, Joyce O’Shaughnessy	2013	92
4	Cytokine induction by 41.8 °C whole body hyperthermia Cancer Letters ·H. Ian Robins, M Kutz, Günther Wiedemann, Dörthe M. Katschinski, Devchand Paul, E.A. Grosen, Cynthia L. Tiggelaar, David R. Spriggs, Wilma Gillis, Floriane d' Oleire	1995	78
5	Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study Breast Cancer Research and Treatment ·Georgiana K. Ellis, Henry G. Bone, Rowan T. Chlebowski, Devchand Paul, Silvana Spadafora, Michelle Fan, Dennis Kim	2009	74
6	Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine Clinical Cancer Research ·Joyce O’Shaughnessy, Hartmut Koeppen, Yuanyuan Xiao, Mark R. Lackner, Devchand Paul, Christopher Stokoe, John Pippen, Lea Krekow, Frankie A. Holmes, Svetislava J. Vukelja, Deborah Lindquist, Scot Sedlacek, Ragene Rivera, Robert J. Brooks, Kristi McIntyre, Carrie Brownstein, Silke Hoersch, Joanne L. Blum, Stephen E. Jones	2015	37
7	Clinical Experience With Image-Guided Radiotherapy in an Accelerated Partial Breast Intensity-Modulated Radiotherapy Protocol International Journal of Radiation OncologyBiologyPhysics ·Charles E. Leonard, Michael Tallhamer, Tim Johnson, Kari Hunter, Kathryn Howell, Jane M. Kercher, Jodi Widener, Terese I. Kaske, Devchand Paul, Scot Sedlacek, Dennis L. Carter	2009	32
8	Ramucirumab With Eribulin Versus Eribulin in Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane Therapy: A Multicenter, Randomized, Phase II Study Clinical Breast Cancer ·Denise A. Yardley, James A. Reeves, Elizabeth Claire Dees, Cynthia R. Osborne, Devchand Paul, Foluso O. Ademuyiwa, Hatem Soliman, Troy H. Guthrie, Jay Andersen, Lea Krekow, J. K. Choksi, Brooke Daniel, Michael Danso, Anne Favret, Sanjay P. Oommen, Adam Brufsky, Jane Bromund, Yong Lin, Ayman Ibrahim, Paul Richards	2016	29
9	A Randomized Phase II Study of Paclitaxel and Bevacizumab With and Without Gemcitabine as First-Line Treatment for Metastatic Breast Cancer Clinical Breast Cancer ·Adam Brufsky, Karen Hoelzer, Thaddeus Beck, Robert C. Whorf, Mark Keaton, P. Nadella, Elisa Krill-Jackson, Joan F. Kroener, Edward L. Middleman, Michael S. Frontiera, Devchand Paul, Timothy J. Panella, Jane Bromund, Luping Zhao, Mauro Orlando, Fritz Tai, Martin Marciniak, Coleman K. Obasaju, John D. Hainsworth	2011	25
10	Phase II Trial of Gemcitabine/Carboplatin (plus Trastuzumab in HER2-Positive Disease) in Patients with Metastatic Breast Cancer Clinical Breast Cancer ·David Loesch, Lina Asmar, Kristi McIntyre, Lisa L. Doane, Michael Monticelli, Devchand Paul, Svetislava J. Vukelja, Mauro Orlando, LaTrice G. Vaughn, Feng Zhan, Kristi A. Boehm, Joyce O’Shaughnessy	2008	24
11	Impact of Weight Loss on Plasma Leptin and Adiponectin in Overweight-to-Obese Post Menopausal Breast Cancer Survivors Nutrients ·Henry J. Thompson, Scot Sedlacek, Pamela Wolfe, Devchand Paul, Susan G. Lakoski, Mary C. Playdon, John N. McGinley, Shawna B. Matthews	2015	24
12	The Effect of Tamoxifen or Exemestane on Bone Mineral Density During the First 2 Years of Adjuvant Treatment of Postmenopausal Women with Early Breast Cancer Clinical Breast Cancer ·Stephen E. Jones, Christopher Stokoe, Mark D. Sborov, Marcus Braun, Sukumar Ethirajan, Leila A. Kutteh, John Pippen, Mrugesh Patel, Devchand Paul, Joanne L. Blum, Frankie A. Holmes, Mark C. Myron, James Cantrell, Nichole L. Hartung, Regan M. Look, E. Di Salle, Jennifer C. Davis, D. Ilegbodu, Lina Asmar	2008	20
13	Effect of dietary patterns differing in carbohydrate and fat content on blood lipidand glucose profiles based on weight-loss success of breast-cancer survivors Breast Cancer Research ·Henry J. Thompson, Scot Sedlacek, Devchand Paul, Pamela Wolfe, John N. McGinley, Mary C. Playdon, Elizabeth A Daeninck, Sara N Bartels, Mark R Wisthoff	2012	20
14	Dose-dense doxorubicin and cyclophosphamide followed by dose-dense albumin-bound paclitaxel plus bevacizumab is safe as adjuvant therapy in patients with early stage breast cancer Breast Cancer Research and Treatment ·John Pippen, Devchand Paul, Svetislava J. Vukelja, Alicia Clawson, José Iglesias	2011	16
15	Abstract S3-07: Letrozole plus dasatinib improves progression-free survival (PFS) in hormone receptor-positive, HER2-negative postmenopausal metastatic breast cancer (MBC) patients receiving first-line aromatase inhibitor (AI) therapy Cancer Research ·Devchand Paul, SJ Vukelja, FA Holmes, Joanne L. Blum, McIntyre Kj, Kumar Ar, DL Lindquist, CR Osborne, IJ Sanchez, JH Goldschmidt, Y Wang, Lina Asmar, Lee Me, Nan Wu, Keith Logie, Joyce O’Shaughnessy	2013	16
16	Final results of a phase 2 study of ramucirumab (RAM) plus eribulin (E) versus E in advanced metastatic breast cancer (MBC). Journal of Clinical Oncology ·Denise A. Yardley, Paul Richards, James A. Reeves, Elizabeth Claire Dees, Cynthia R. Osborne, Hatem Soliman, Devchand Paul, Foluso O. Ademuyiwa, Troy H. Guthrie, Jane Bromund, Yihuan Xu, Ayman Ibrahim	2014	16
17	Evaluation of Miracle Mouthwash plus Hydrocortisone Versus Prednisolone Mouth Rinses as Prophylaxis for Everolimus-Associated Stomatitis: A Randomized Phase II Study The Oncologist ·Vicky Jones, Kristi McIntyre, Devchand Paul, Sharon Wilks, Sharon M. Ondreyco, Scot Sedlacek, Anton Melnyk, Sanjay P. Oommen, Yunfei Wang, Susan Peck, Joyce O’Shaughnessy	2019	15
18	Interim joint analysis of the ABC (anthracyclines in early breast cancer) phase III trials (USOR 06-090, NSABP B-46I/USOR 07132, NSABP B-49 [NRG Oncology]) comparing docetaxel + cyclophosphamide (TC) v anthracycline/taxane-based chemotherapy regimens (TaxAC) in women with high-risk, HER2-negative breast cancer. Journal of Clinical Oncology ·Joanne L. Blum, Patrick J. Flynn, Greg Yothers, Lina Asmar, Charles E. Geyer, Samuel A. Jacobs, Nicholas J. Robert, James N. Atkins, Joyce O’Shaughnessy, Chau T. Dang, Henry Gómez, Louis Fehrenbacher, Svetislava J. Vukelja, Alan P. Lyss, Devchand Paul, Adam Brufsky, Sandra M. Swain, Eleftherios P. Mamounas, Stephen E. Jones, Norman Wolmark	2016	14
19	Weight Loss Interventions for Breast Cancer Survivors: Impact of Dietary Pattern PLoS ONE ·Henry J. Thompson, Scot Sedlacek, Mary C. Playdon, Pamela Wolfe, John N. McGinley, Devchand Paul, Susan G. Lakoski	2015	11
20	Randomized phase-II evaluation of letrozole plus dasatinib in hormone receptor positive metastatic breast cancer patients npj Breast Cancer ·Devchand Paul, Svetislava J. Vukelja, Frankie A. Holmes, Joanne L. Blum, Kristi McIntyre, Deborah Lindquist, Cynthia R. Osborne, Ines J. Sanchez, Jerome H. Goldschmidt, Yunfei Wang, Lina Asmar, Lewis C. Strauss, Joyce O’Shaughnessy	2019	11

About Devchand Paul

Devchand Paul is a scholar working on Cancer Research, Oncology, Genetics, Pulmonary and Respiratory Medicine and Orthopedics and Sports Medicine, having authored 34 papers that have together received 1.0k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (14 papers), Cancer Treatment and Pharmacology (13 papers), HER2/EGFR in Cancer Research (13 papers), Estrogen and related hormone effects (8 papers), Advanced Breast Cancer Therapies (7 papers), Bone health and treatments (5 papers), Colorectal Cancer Treatments and Studies (3 papers) and Cancer Genomics and Diagnostics (3 papers). The work is most often cited by research in Oncology (819 citations), Orthopedics and Sports Medicine (224 citations), Cancer Research (264 citations), Radiology, Nuclear Medicine and Imaging (171 citations) and Pulmonary and Respiratory Medicine (203 citations). Devchand Paul has collaborated with scholars based in United States, United Kingdom and Peru. Frequent co-authors include Silvana Spadafora, Georgiana K. Ellis, Rowan T. Chlebowski, Michelle Fan, Henry G. Bone, J. W. G. Smith, Susie Jun, Scot Sedlacek, Svetislava J. Vukelja and Nicholas J. Robert. Their work appears in journals such as Journal of Clinical Oncology, Clinical Breast Cancer, Cancer Research, Breast Cancer Research and Treatment and International Journal of Radiation Oncology*Biology*Physics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact